Clinical Trial Update: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled trial evaluating ambrisentan for pulmonary arterial hypertension has completed; the update does not provi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

Sponsor: Gilead Sciences | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED